ACCELERON PHARMA INC

Form 4

November 21, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Estimated average

Expires:

OMB APPROVAL

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

January 31,

2005

Section 16.
Form 4 or
Form 5
obligations

may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

See Instruction 1(b).

(City)

(State)

(Zip)

(Print or Type Responses)

1. Name and Address of Reporting Person * MCGUIRE TERRANCE			2. Issuer Name and Ticker or Trading Symbol ACCELERON PHARMA INC [XLRN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) ONE MARIN SUITE 1100	ONE MARINA PARK DRIVE,		3. Date of Earliest Transaction (Month/Day/Year) 11/17/2016	X Director 10% Owner Officer (give title Other (specify below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
BOSTON, MA 02210				Person			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	Table I - Non-Derivative Securities Acquired, D	Disposed of, or Beneficially Owned
--	---	------------------------------------

						-	· •		Ť
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4	osed c	of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	11/17/2016		J <u>(1)</u>	693,020 (2)	D	\$0	605,133 (3)	I	See Footnote (4)
Common Stock	11/18/2016		J <u>(5)</u>	6,980 (5)	D	\$ 0	598,153 <u>(6)</u>	I	See Footnote
Common Stock	11/18/2016		J <u>(5)</u>	1,624	A	\$0	1,624	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: ACCELERON PHARMA INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. orNumber	6. Date Exerc Expiration Da		7. Titl		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Teal)	any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/		Under	lying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

MCGUIRE TERRANCE
ONE MARINA PARK DRIVE, SUITE 1100 X
BOSTON, MA 02210

Signatures

/s/ Mary Blair, Attorney in-Fact for Terrance McGuire

11/21/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

L.P. ("PVP IV") and Polaris Venture Partners Entrepreneurs' Fund IV, L.P. ("PVPE IV" and, together with PVP IV, the "Funds") to their respective limited partners. In addition, in connection with the above mentioned distribution, each of, PVP IV distributed 6,850 shares and PVPE IV distributed 130 shares to Polaris Venture Management Co. IV, L.L.C. ("PVM IV"). The distribution of these 6,980 shares by PVP IV and PVPE IV to PVM IV is an exempt transaction and not reported in column 4 because the transaction merely reflected a change in the beneficial ownership of those shares.

Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners IV,

- Represents 680,269 shares distributed by PVP IV to its limited partners and 12,751 shares distributed by PVPE IV to its limited partners.
- (3) Represents 586,056 shares, 10,102 shares, and 8,975 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively.

Reporting Owners 2

Edgar Filing: ACCELERON PHARMA INC - Form 4

- The Reporting Person is a managing member of PVM IV, the general partner of each of PVP IV and PVPE IV. The Reporting

 Person disclaims beneficial ownership of the Funds' and PVM IV's securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest, if any, therein.
- (5) Represents a pro rata distribution, and not a purchase or sale, without additional consideration by PVM IV to its members and assignees.
- (6) Represents 586,056 shares, 10,102 shares, and 1,995 shares directly owned by PVP IV, PVPE IV and PVM IV, respectively.

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.